Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05930145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
This record was last updated July 28, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.
Record History
MinorRe-verified, no change to tracked fieldsv5
NotableLead sponsor: Hospital Universitario Central de Asturias to Fundación EPICTrial status: Not Yet Recruiting to Recruiting · Primary completion date: Sep 1, 2024 to Sep 1, 2026 · Start date changed from estimate of Sep 1, 2023 to Mar 14, 2025 · 2 morev4Show 5 more changesShow less
Trial status: Not Yet Recruiting to Recruiting
Primary completion date: Sep 1, 2024 to Sep 1, 2026
Start date changed from estimate of Sep 1, 2023 to Mar 14, 2025
Study sites: 0 to 4
Completion date: Sep 1, 2024 to Oct 1, 2026
MinorSecondary endpoints: details revised at 10 of 12 entriesv3
NotableStart date: Jul 1, 2023 to Sep 1, 2023Primary endpoints revised (2) · Primary and study completion dates: Jul 1, 2024 to Sep 1, 2024 · Secondary endpoints: 14 to 12 · 2 morev2Show 5 more changesShow less
Primary endpoints revised (2)
Primary and study completion dates: Jul 1, 2024 to Sep 1, 2024
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c/3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.